Prevalence of Hepatitis B and C among HIV Infected Pregnant Women Attending Care and Treatment at National Institute for Pharmaceutical Research and Development (NIPRD), Abuja, Nigeria

Main Article Content

Y. Ya’aba
S. B. Mohammed
K. T. Olatunji
A. Abubakar
M. Usoroh
O. C. Daniel
A. R. Abdulmumin
J. F. Nfongeh

Abstract

Introduction: Viral Hepatitis and Human Immunodeficiency Virus (HIV) are most common top ranking leading causes of infectious diseases and deaths worldwide. If these infections, remain unidentified and untreated among HIV infected pregnant women, children born to these pregnant women are at high risk of these viral hepatitis infections.

Aims: The aim of the study was to determine the sero-prevalence of HBV and HCV among HIV infected pregnant women in Abuja, Nigeria.

Methodology: A cross sectional study among 330 HIV infected pregnant women commencing antiretroviral therapy (ART) at National Institute for Pharmaceutical Research and Development (NIPRD), Abuja, Nigeria were studied. The women were screened for the presence of HBV and HCV antibodies. A pre-tested questionnaire was used to obtain socio-demographic data prior to recruitment/enrollment. Data were analyzed using statistical product and service solutions (SPSS) (version 20.0).

Results: Out of the 330 HIV infected pregnant women, 90 (27.3%) were HBV positive, while 5 (1.5%) were HCV positive (p = 0.42). The highest prevalence was observed among the age group of 20 – 29. However, none of the patients tested positive for both HBV and HCV.

Conclusion: The findings of this study indicated that infection with viral hepatitis is common and of public health concern. Therefore, concerted efforts should be put in place to mitigate the epidemics.

Keywords:
Hepatitis B virus, hepatitis C virus, human immune deficiency virus, sero-prevalence, cross sectional, NIPRD

Article Details

How to Cite
Ya’aba, Y., Mohammed, S. B., Olatunji, K. T., Abubakar, A., Usoroh, M., Daniel, O. C., Abdulmumin, A. R., & Nfongeh, J. F. (2019). Prevalence of Hepatitis B and C among HIV Infected Pregnant Women Attending Care and Treatment at National Institute for Pharmaceutical Research and Development (NIPRD), Abuja, Nigeria. Microbiology Research Journal International, 28(4), 1-8. https://doi.org/10.9734/mrji/2019/v28i430137
Section
Original Research Article

References

WHO. The world health report; 2011.

(Accessed October, 2012)

Available:www.who.int/whr/2002/annex/en/

Sadoh AE, Sadoh WE, Iduoriyekemwen NJ. HIV co-infection with hepatitis B and C viruses among Nigerian children in an antiretroviral treatment programme. SAJCH. 2011;5(1):7-10.

Jombo GTA, Egah DZ, Banwat EB. Hepatitis B virus and Human Immuno-deficiency Virus co-infection in Zawan community of Plateau state. J Med Trop. 2005;7(1):21-26.

Destang JL. Hepatitis B virus infection. N Engl J Med. 2008;359:1486-1500.

Nwokedi EOP, Odimayo MS, Emokpae AM, Yahaya IA, Sadiq MN, Okwori EE. Seroprevalence of Hepatitis B surface Antigen among patients attending Aminu Kano. Niger J Med. 2010;19(4):28-36.

Taiwo MB, Samuel E, Emmanuel FO. HIV, Hepatitis B and C viruses’ co- infection among patients in a Nigerian tertiary hospital. Pan Afr Med J. 2012;12:100.

Gatanaga H, Yasuoka A, Kikuchi Y, Tachikawa N, Oka S. Influence of prior HIV-1 infection on the development of chronic hepatitis B infection. Eur J Clin Microbiol. 2000;19(3):237-9.

Rotman Y, Liang TJ. Coinfection with hepatitis C virus and humanimmuno-deficiency virus: Virological immunological, and clinical outcomes. J Virol. 2009; 83(15):7366-74.

Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M. Factors associated with specific causes of death amongst HIV-positive individuals in the D: A: D Study. AIDS. 2010;24(10):1537-48.

Shawa IT. Hepatitis B and C viruses. In Hepatitis B and C. Mar 1. Intech Open; 2019.

World Health Organization Fact Sheet No. 204; 2018.

Available:http://www.uath.ng.org

[Last accessed on 2018 Jan 20]

World Health Organization. “Hepatitis B vaccines,” in Weekly Epidemiological Record. 2009;40:405–420.

Shawa IT, Hopkins M. Evaluation of hepatitis C virus genotyping protocols for use in a diagnostic setting. Int J Med Res. 2013;1(1):2-7.

Imade GE, Sagay AS, Ugwu BT, Thacher TD, Ford RW. Seroprevalence of hepatitis B and human immunodeficiency virus infections in pregnant women in Nigeria. Journal of Medic in the Tropics. 2004; 6(2):15-21.

Joint United Nations Programme on HIV/AIDS. Report on the global AIDS epidemic. Geneva, Switzerland: UNAIDS; 2010.

Available:http://www.unaids. org/globalreport/Global_report. htm

Wilcox RD. Hepatitis B co-infection in pregnancy. HIV Clinician. 2010;22(1):5-6.

Nwokedi EE, Epopees MA, Dutse AI. Human immunodeficiency virus and hepatitis B virus co infection among patients in Kano, Nigeria. Niger J Med. 2006;15(3):227- 9.

Lesi OA, Kehinde MO, Oguh DN, Amira CO. Hepatitis B and C virus infection in Nigerian patients with HIV/AIDS. Niger Postgrad Med J. 2007;14(2):129-33.

Balogun TM, Emmanuel S, Ojerinde EF. HIV, Hepatitis B and C viruses? co-infection among patients in a Nigerian tertiary hospital. The Pan African Medical Journal. 2012;12:100.

Denue BA, Ajayi B, Abja AU, Bukar AA, Akawu C, Ekong E, Alkali MB. A survey of Hepatitis B and C virus prevalence in Human immunodeficiency virus positive patients in a Tertiary health institution in North Eastern Nigeria. International Journal of Medicine and Medical Sciences. 2012;4(1):13-18.

Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, Koziel MJ. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. Clin Infect Dis. 2001;33(4): 562-569.

Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated withnevirapine or efavirenz containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology. 2002;36(1):512-513.

Zimmerman RK, Ruben FL, Ahwesh ER. Hepatitis B Virus Infection, hepatitis B vaccine and hepatitis B immune globulin. J Fam Pract. 1997;45(4):295-315.

Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, Thomas DL. HIV-1, Hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360(9349):1921-1926.

Gambarin-Gelwan M. Hepatitis B in pregnancy. Clin Liver Disease. 2007; 11:945-63.

National Institute for Health and Clinical Excellence (NICE) (2008). Antenatal Care. Routine Care for Healthy Pregnant women. London: RCCG Press: National Collaborating Centre for Women’s and Children’s Health. 2008;454-621.

Available:http://www.uath.ng.org

[Last accessed on 2015 Jan 18]

Tse KY, Ho LF, Lao T. The impact of maternal HBsAg carrier status on pregnancy outcomes: A case-control study. J Hepatol. 2005;43:771-5.

Konopnicki D, Mocroft A, de Wit S. Hepatitis B and HIV: Prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the Euro SIDA cohort. AIDS. 2005;19(6):593-601.

Petrovic LM. HIV/HCV co-infection: Histopathologic findings, natural history, fibrosis, and impact of antiretroviral treatment: A review article. Liver Int. 2007; 27(5):598-606.

Henry. The free online encyclopaedia. 5th Edition, New York; 2008.

World Health Organization. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Journal on Viral Hepatitis. Antwerp, Belgium. 1999;6:35-47.

Tremeau-Bravard A, Ogbukagu IC, Ticao CJ, Abubakar JJ. Seroprevalence of hepatitis B and C infection among the HIV-positive population in Abuja, Nigeria. African Health Sciences. 2012;12(3):312-317.

Eke AC, Eke UA, Okafor CI,et al. Prevalence correlates and pattern of hepatitis B surface antigen in a low resource setting. Virology. 2011;8:1215.

Pirillo MF, Bassani L, Germinario EA, Mancini MG, Vyankandondera J, Okong P, Vella S, Giuliano M. Seroprevalence of hepatitis B and C viruses among HIV infected pregnant women in Uganda and Rwanda. J Med Virol. 2007;79(12):1797-801.

Landes M, Newell ML, Barlow P, Fiore S, Malyuta R, Martinelli P. Hepatitis B or hepatitis C co-infection in HIV-infected pregnant women in Europe. HIV Medicine. 2008;9(7):526534.

Adesina O, Oladokun A, Akinyemi O, Adedokun B, Awolude O, Odaibo G, Olaleye D, Adewole. Human immuno-deficiency virus and hepatitis B virus coinfection in pregnancy at the University College Hospital, Ibadan. Afr J Med Med Sci. 2010;39(4):30510.

Rouet F, Chaix ML, Inwoley A, Msellati P, Viho I, Combe P, Leroy V, Dabis F. HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Côte d'Ivoire: The ANRS 1236 study. J Med Virol. 2004;74(1):34-40.

Ezegbudo CN, Agbonlahor DE, Nwobu G, Igwe CU, Agba MI, Okpala HO, Ikaraoha CI. The seroprevalence of hepatitis B surface antigen and human immuno-deficiency virus among pregnant women in Anambra State Nigeria. Shiraz E-Medical Journal. 2004;5(5):1-8.

Anaedobe CG, Fowotade A, Omoruyi CE, Bakare RA. Prevalence, sociodemographic features and risk factors of hepatitis B virus infection among pregnant women in Southwestern Nigeria. Pan Afr Med J. 2015;20:406.

Edris A, Nour MO, Zedan OO, Mansour AE, Ghandour AA, Omran T. Sero-prevalence and risk factors for hepatitis B and C virus infection in Damietta Governorate, Egypt. East Mediterr Health J. 2014;20:605-13.

Monga HK, Rodriguez-Barradas MC, Breaux K. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;33: 240-7.

Chen TY, Ding EL, Seage GR, Kim AY. Metaanalysis: Increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis, 2009;49(10): 1605–1615.